The PARADIGM-HF trial prospectively compared angiotensin receptor-neprilysin inhibitor (ARNI) and ACE inhibition to determine their impact on overall mortality and incidence rate of HF, consistent with the concept of CRS described by Ronco et al. Here, ACE is linked to hydrops fetalis.